Research shows: Rifaximin prophylaxis drives resistance to daptomycin, an unrelated, last-resort antibiotic
Rifaximin is used for hepatic encephalopathy in liver patients at high risk for infections, including VRE treated with daptomycin. The antibiotic was thought to pose a low resistance risk
www.nature.com
Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
